Affinity Asset Advisors LLC Has $10.15 Million Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Affinity Asset Advisors LLC boosted its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 4.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,407 shares of the company’s stock after acquiring an additional 8,818 shares during the quarter. Establishment Labs accounts for approximately 1.2% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 23rd biggest holding. Affinity Asset Advisors LLC owned approximately 0.81% of Establishment Labs worth $10,152,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ESTA. Hood River Capital Management LLC bought a new position in shares of Establishment Labs in the second quarter valued at about $43,000. California State Teachers Retirement System lifted its position in Establishment Labs by 14.5% during the first quarter. California State Teachers Retirement System now owns 17,096 shares of the company’s stock worth $870,000 after acquiring an additional 2,167 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Establishment Labs by 13.6% during the first quarter. Swiss National Bank now owns 37,500 shares of the company’s stock worth $1,909,000 after acquiring an additional 4,500 shares during the period. Nkcfo LLC acquired a new position in shares of Establishment Labs in the second quarter valued at approximately $227,000. Finally, Concurrent Investment Advisors LLC bought a new position in shares of Establishment Labs during the first quarter worth approximately $263,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Insider Activity

In other Establishment Labs news, CEO Quiros Juan Jose Chacon sold 3,866 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $45.01, for a total value of $174,008.66. Following the sale, the chief executive officer now owns 215,030 shares in the company, valued at $9,678,500.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 14,346 shares of company stock worth $647,806. Corporate insiders own 11.44% of the company’s stock.

Establishment Labs Stock Performance

Shares of Establishment Labs stock opened at $39.77 on Wednesday. The company has a 50 day moving average of $43.33 and a 200-day moving average of $47.46. The company has a quick ratio of 2.91, a current ratio of 4.44 and a debt-to-equity ratio of 4.30. Establishment Labs Holdings Inc. has a 1-year low of $16.96 and a 1-year high of $60.12.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The business had revenue of $44.12 million for the quarter, compared to analyst estimates of $43.10 million. Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. Establishment Labs’s quarterly revenue was down 9.2% on a year-over-year basis. During the same period last year, the firm posted ($0.65) EPS. Research analysts expect that Establishment Labs Holdings Inc. will post -2.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on ESTA shares. Citigroup boosted their price target on Establishment Labs from $41.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. JPMorgan Chase & Co. lowered their price target on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Mizuho lifted their price objective on shares of Establishment Labs from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, June 6th. Finally, Stephens restated an “overweight” rating and set a $68.00 target price on shares of Establishment Labs in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus price target of $56.60.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.